XOMA (NASDAQ:XOMA – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
Several other research firms also recently commented on XOMA. SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an “outperform” rating and a $40.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $74.00 target price on shares of XOMA in a report on Tuesday, July 9th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of XOMA in a report on Monday, April 29th.
Get Our Latest Stock Analysis on XOMA
XOMA Stock Down 1.1 %
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in XOMA during the first quarter valued at approximately $212,000. Bank of New York Mellon Corp raised its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. Finally, Rhumbline Advisers raised its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.
XOMA Company Profile
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Further Reading
- Five stocks we like better than XOMA
- EV Stocks and How to Profit from Them
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Stocks That Could Beat the September Blues
- Most Volatile Stocks, What Investors Need to Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.